SwissDock, a protein-small molecule docking web service based on EADock DSS by Grosdidier, Aurélien et al.
SwissDock, a protein-small molecule docking
web service based on EADock DSS
Aure ´lien Grosdidier
1, Vincent Zoete
1,* and Olivier Michielin
1,2,3,*
1Swiss Institute of Bioinformatics (SIB), Quartier Sorge, Ba ˆtiment Ge ´nopode, CH-1015 Lausanne,
2Ludwig Institute for Cancer Research, Ltd and
3Pluridisciplinary Center for Clinical Oncology (CePO),
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Received February 24, 2011; Revised April 12, 2011; Accepted April 27, 2011
ABSTRACT
Most life science processes involve, at the atomic
scale, recognition between two molecules. The pre-
diction of such interactions at the molecular level,
by so-called docking software, is a non-trivial task.
Docking programs have a wide range of applica-
tions ranging from protein engineering to drug de-
sign. This article presents SwissDock, a web server
dedicated to the docking of small molecules on
target proteins. It is based on the EADock DSS
engine, combined with setup scripts for curating
common problems and for preparing both the target
protein and the ligand input files. An efficient Ajax/
HTML interface was designed and implemented so
that scientists can easily submit dockings and re-
trieve the predicted complexes. For automated
docking tasks, a programmatic SOAP interface has
been set up and template programs can be down-
loaded in Perl, Python and PHP. The web site also
provides an access to a database of manually
curated complexes, based on the Ligand Protein
Database. A wiki and a forum are available to the
community to promote interactions between users.
The SwissDock web site is available online at http://
www.swissdock.ch. We believe it constitutes a step
toward generalizing the use of docking tools beyond
the traditional molecular modeling community.
INTRODUCTION
Molecular docking
Back in the 19th century, Emil Fischer introduced the
lock-and-key model to explain enzyme speciﬁcity.
Nowadays, it is well known that most of the processes
in life sciences involve, at the atomic scale, complex
interactions between at least two molecules. The predic-
tion of such interactions, by so-called docking software, is
a non-trivial task. Docking programs intrinsically have a
wide range of applications that go far beyond the creation
of simple visual illustrations. In the context of protein
engineering, for instance, the prediction of the detailed
molecular interactions between a protein and one of its
interacting partners paves the way for the rational selec-
tion of amino acids that could be mutated to promote or
disrupt this interaction (1,2). Conversely, a small molecule
interacting with a protein can be modiﬁed in order to
change its afﬁnity and, in ﬁne, its biological activity to
obtain new molecular probes or drugs (3–9). In addition,
by docking the same compound into several protein
targets, one can gain insights into the underlying molecu-
lar mechanisms of selectivity (10). The properties of the
predicted complex can also be investigated by further cal-
culations, so that complex recognition mechanisms might
be unveiled. For instance, a recent MD simulation study
allowed a better understanding of the molecular switch
involving the helix 12 of the peroxisome proliferator-
activated receptor alpha (11). Lastly, docking predictions
can be post-processed using free energy calculations. For
example, several b-secretase (BACE) and HIV-1 protease
(HIV-1 PR) inhibitors have been identiﬁed by such a
combination (12,13).
Current limitations to widespread use
While docking programs have already been very helpful in
drug design (14), their wide and general usage remains
impaired by the steep learning curve still required before
being able to setup, carry out and analyze a docking assay.
This technical barrier is due to the following caveats:
Structure setup. First, a docking assay requires the struc-
ture of a target protein. Of total, 87% of those available in
the most comprehensive resource, the Protein Databank
[(15) as of November 2010], have been obtained by X-ray
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ments in this ﬁeld, most of these structures usually do
not meet the quality criteria required for a modeling
study. For instance, some atoms in the ﬂexible part of
the protein are not resolved and the corresponding
spatial coordinates omitted in the PDB ﬁle. The orienta-
tion of asparagine, glutamine and histidine side chains,
as well as the position of water molecules should be con-
sidered with caution since their determinations remain
challenging for X-ray crystallography (16). Crystal
packing may also lead to constrained structures, and the
crystallization conditions (solvent, pH and concentration)
might differ considerably from in vivo conditions (16). A
careful investigation of all these issues is required before
carrying out the docking assay, and a molecular modeling
background is required to reconstruct and correct the de-
fective parts of the structure (16). Similarly, the structure
of the ligand must also be carefully inspected to make sure
that the topology of the molecule is correct, as well as its
protonation state and tautomeric form. Both the setup of
the protein structure and the ligand require a sufﬁcient
understanding of biophysics as well as organic and/or me-
dicinal chemistry, which often prevents docking software
from being used by a wide audience beyond the limits of
molecular modeling experts.
Software’s speciﬁc use. Additionally, once the two struc-
tures have been setup, several docking parameters must be
deﬁned, such as the region of space to which the docking
search space will be limited, the exhaustiveness of the
conformational search or the maximum duration of the
docking assay. Most docking programs are complex com-
putational machineries and require speciﬁc additional sam-
pling or scoring parameters to which they might be very
sensitive. While convenient default values are often pro-
posed, a good understanding of the user manual and/or
of the original article is always required in order to ac-
hieve meaningful predictions. Therefore, extensive practice
is generally essential to perform relevant and reliable
dockings.
Once all parameters have been deﬁned, calculations are
usually started from a command line interface that might
discourage non-specialists, and may require computing
power beyond that of common personal computers.
Embedding predictions in an existing research
pipeline. Expectationsregardingdockingpredictionsrange
from illustrating a hypothesis up to prioritizing com-
pounds according to their putative biological activity.
While docking software has proven to be a valuable tool
for drug development (3–9,17), the visualization, classiﬁ-
cation and rational analysis of their predictions often
remain so challenging that only a tiny fraction of them
can be properly incorporated into existing research
pipelines.
The SwissDock web server
A large interest for docking web servers has emerged
recently, as can be seen through the growing list of similar
web services currently available, such as DockingServer
(http://www.dockingserver.com/web), Blaster (18),
DockingAtUTMB (http://docking.utmb.edu/), Pardock
(http://www.scfbio-iitd.res.in/dock/pardock.jsp),
PatchDock (http://bioinfo3d.cs.tau.ac.il/PatchDock/),
MetaDock (http://dock.bioinfo.pl/), PPDock (http://140.
112.135.49/ppdock/index.html) and MEDock (http://
medock.ee.ncku.edu.tw/) (a comprehensive list is being
kept up to date on the click2drug web portal, http://
www.click2drug.org).
With the SwissDock web site, we aim at extending the
use of protein-small molecule docking software far beyond
experts in the ﬁeld by providing convenient answers to
many of the difﬁculties mentioned above. First,
manually curated protein structures can be downloaded
from the web site, and original PDB ﬁles can be
prepared through ad hoc scripts (19,20). Second, the
docking software is easily accessible through either a
web browser or a programmatic interface. Third, pre-
dicted binding modes (BMs) can be viewed online with a
simple embedded applet or analyzed in more details
thanks to a seamless integration with the UCSF
Chimera molecular viewer (21), with the help of the
online documentation and the user community.
SWISSDOCK
SwissDock is a docking web server that addresses the limi-
tations described above. The structure of the target pro-
tein, as well as that of the ligand, can be automatically
prepared for docking. In addition, the cumbersome syntax
of the docking engine is hidden behind a clean web inter-
face providing reasonable alternative sets of parameters as
well as sample input ﬁles. All calculations are performed
on the server side, so that docking runs do not require any
computational power from the user. The interpretation of
docking results and their integration into existing research
pipelines is greatly facilitated by the seamless visualization
of docking predictions in the UCSF Chimera molecular
viewer, which can be launched directly from the web
browser.
Web interface
Inputs. Only three steps are required to start a docking
assay through the web interface of SwissDock: users must
deﬁne a protein structure, one or several putative ligands
and docking parameters (Figure 1). They are guided
throughout this short and simple submission process
by a comprehensive contextual help. As mentioned
above, several sample ﬁles are supplied to users and can
be directly uploaded into the form simply by clicking on a
link. The corresponding sample output ﬁles are also
provided.
Target selection. A target protein structure can be
determined either by specifying its identiﬁer from the
Protein Data Bank (15) or by uploading structure ﬁles.
The ﬁrst option allows users who are not familiar with
3D structure ﬁles to start a docking assay with only a PDB
code. If several PDB records are available for the same
target, those with a high resolution and a ligand similar to
the one that will be docked should be considered ﬁrst.
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can specify the identiﬁers of those on which the docking
will be performed. If the structure ﬁle has been generated
by nuclear magnetic response experiment, it must be
edited ﬁrst to keep only one structural model.
The second option allows the uploading of user-deﬁned
or edited target structures. Since the calculations are per-
formed in the CHARMM force ﬁeld, SwissDock supports
the uploading of CHARMM formatted ﬁles in addition to
the commonly used PDB format: protein structures can be
uploaded as a set of protein structure ﬁle (PSF), coordin-
ate ﬁle (CRD) and extra topology (RTF) and parameter
ﬁles (PAR), if needed. A high-quality library of 260
protein complexes that have been manually curated (22)
can be downloaded in the CHARMM format from the
SwissDock web site.
Once the target protein structure has been deﬁned, it is
immediately prepared for use with CHARMM, and the
curated structure can be downloaded and reviewed prior
to the docking assay if needed (see ‘Materials and
methods’ section for details).
Ligand selection. A ligand can be selected either by spe-
cifying its identiﬁer from the ZINC database (23) or by up-
loading structure ﬁles. The former possibility allows users
who are not familiar with 3D structure ﬁles to start a
docking assay with only a ZINC accession code (AC).
The latter allows uploading several ligands at once or up-
loading ligands that are not present in the ZINC database.
As for the target protein, SwissDock not only supports
the widely used Mol2 format, but also the direct upload of
CHARMM input ﬁles describing the ligand: a coordinate
ﬁle (PDB), extra topology (RTF) and parameter ﬁles
(PAR). The ligand is immediately set up after its deﬁnition
and its prepared structure can be downloaded and
reviewed prior to the docking assay, if needed (see
‘Materials and methods’ section for details).
Docking parameters
Docking type. Three docking parameter presets can be
selected: very fast, fast and accurate. They correspond to
presets described previously (20). In brief, several docking
parameters are adjusted in order to reach the desired
docking time and exhaustiveness of the search: the
number of sampled BMs, the number of minimization
steps that are performed to relax the ligand and the
number of predicted BMs. If the ligand has less than 15
rotatable bonds and/or is likely to ﬁt exactly into a
binding pocket of the target protein, the very fast and
fast modes are most probably sufﬁcient (see below).
Figure 1. (A) Screenshot of the job submission form. It is dynamically modiﬁed so that the user can replace the default target selection from PDB
codes by a target upload form (B). Similarly, the default ligand selection from ZINC codes can be replaced either by a ligand upload form (C)o rb y
a fragment selection form (D) if a screening assay is to be performed. In such a case, the fragments to dock can be manually selected (E). The
contextual help is automatically adapted to submission form content.
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parameters, the whole target protein structure is con-
sidered during the docking. However, if the target protein
is particularly large and/or if the putative binding pocket
is already known, the docking can be restricted to an rect-
angular region of space to perform a local docking assay.
Outputs. After a docking assay has been submitted, it can
be tracked thanks to a dedicated URL provided on the
submission conﬁrmation page. If an (optional) email
address has been speciﬁed in the submission form, this
URL is also sent to the user by email, as well as a link
to the docking result web page once the docking is
completed.
This docking result web page features a Jmol applet (24)
for the visualization of the predicted BMs within the web
browser (Figure 2A). For further visual investigations,
UCSF Chimera can be started by a single click, and the
predicted BMs are automatically loaded in its ViewDock
plugin (Figure 2B). A short video illustrating this process
is available on the SwissDock home page.
Predicted BMs are also available for download as a ZIP
ﬁle. It contains PDB ﬁles for the complex, as well as the
predicted BMs in the DOCK format. For experienced
users, CHARMM PSF/CRD/RTF/PAR ﬁles are also
provided for subsequent calculations.
Community. An online help is available using the form of
a wiki. A searchable forum is proposed to promote com-
munication among users, such as feedbacks, tips and
tricks, questions and answers, so that the experience
gained by some may be shared with others more broadly
than what a mailing list would allow for.
Privacy policy. Uploaded ﬁles and docking predictions
are automatically deleted after 7 days. Other parameters
are kept anonymously for statistical purposes.
SOAP interface
Alongside the web interface, a programmatic access has
been implemented via SOAP. The SwissDock SOAP
server is implemented in the Python programming
language, with the soaplib library. Sample client codes
written in PHP, Perl or Python can be downloaded from
the web site. They rely on the NuSOAP (http://nusoap
.sourceforge.net/), SOAP::WSDL (http://search.cpan.org/
Figure 2. This ﬁgure shows a typical output of SwissDock for the docking of the Guanine nucleotide-binding protein G(q) subunit alpha, a target
involved in uveal melanoma (35). (A) Screenshot of the Jmol applet which renders predicted BMs within the web browser. (B) Visual investigation
using the ViewDock plugin of UCSF Chimera. The predicted BM of the guanosine diphosphate (magenta sticks) is superimposed to the X-ray BM
(ball and sticks). As it can be seen in the lower part of the ﬁgure, this particular predicted BM has the most favorable energy.
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and soaplib libraries (http://pypi.python.org/pypi/soaplib/
0.8.1), respectively.
The server implements the three tasks of setting up the
target protein, setting up the ligand and submitting the
docking. A typical sequence is represented in Figure 3.
Predictive performance assessment
The performance of the backend of SwissDock, i.e.
EADock DSS, was assessed by a blind docking assay on
251 test complexes (22) taken from the Ligand Protein
DataBase (LPDB) (25) with the different presets available
from the web interface: fast, very fast, accurate and very
accurate.
With accurate parameters, the ﬁrst predicted BM was
within 2A ˚ of the crystal structure for 54.5% of the test
complexes, representing the success rate in rank 0 (SR0).
This success rate increased up to 63.7% when the ﬁve most
favorable predicted BMs were considered (SR5). The per-
formance varies depending on the set of parameters and it
is noteworthy that even a very short docking assay already
managed to propose a correct BM for about 50% of the
test complexes. The maximum performance is obtained
for the very accurate parameter preset, with a SR5
slightly above 70%.
The performance of EADock DSS depends on the
number of free dihedral angles of the ligand (Table 1).
The vast majority (93%) of Food and Drug
Administration (FDA)-approved drugs [subset of the
ZINC database as of October 2010 (23)] has <10 rotatable
bonds. The success rates observed for such ligands were
77% for SR0 and 86% for SR5. It is worth noting that the
251 ligands present in our validation set of complexes have
16 free dihedrals on average, making them much harder to
predict. The performance observed here underestimates
what can be expected in a typical drug design docking
assay.
The fraction of the surface of the ligand which becomes
buried upon complexation also has a signiﬁcant effect: the
higher this fraction, the easier it is for SwissDock to
identify the binding pocket, and therefore to dock the
ligand inside (Table 2).
MATERIALS AND METHODS
Algorithm
SwissDock is based on the docking software EADock
DSS (20). Its algorithm consists of the following steps.
First, a large number of BMs (typically from 5000 to
15000) are generated, either in a user-deﬁned box (local
docking) or in the vicinity of the target cavities of the
entire protein surface (blind docking). Simultaneously,
their CHARMM (26) energies are estimated on a grid.
Then, BMs with the most favorable energies are ranked,
taking account of the solvent effect using the FACTS
implicit solvation model (27), and clustered. Finally, the
most favorable clusters are dumped into the result ﬁle.
This unique combination of features allows accurate
docking assays to be carried out within minutes.
Implementation
The SwissDock web server is implemented with open-
source technologies (Apache web server, PHP).
Calculations are currently carried out on 32 computing
nodes with Dual Xeon E5440 2.83GHz and 16 GB of
Figure 3. Sequence diagram of a typical interaction between a
SwissDock SOAP client and the SwissDock SOAP server. The target
preparation, ligand preparation and docking submission tasks can be
performed in a row or independently. Each task is divided into three
steps. First, the client submits the task. Second, it polls the server at
regular intervals in order to know if the task has been processed. If so,
the outcome of the task is retrieved from the server.
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RAM, which belong to the Molecular Modeling group of
the Swiss Institute of Bioinformatics and are integrated
into the Vital-IT cluster.
Input ﬁles preparation
Since docking assays are carried out in the CHARMM22/
27 all-hydrogen force ﬁeld (26), target proteins and ligands
that have been uploaded as CHARMM-formatted ﬁles
can be used as is. Conversely, proteins and ligands that
have been submitted in PDB or Mol2 format, respectively,
have to be converted prior to the docking itself. This pro-
cedure, which generally requires a good knowledge of this
software and of the physico-chemical properties of
proteins and small molecules, is normally performed by
experimented users. However, this step has been auto-
matized for the SwissDock web service and is performed
transparently for the user.
Preparation of the target protein. In short, the PDB struc-
ture ﬁle, either provided by the user or downloaded from
the PDB if a PDB identiﬁer has been provided, is divided
into protein and non-protein parts. The former is further
decomposed into CHARMM segments, which correspond
to protein chains or units. These segments are identiﬁed by
calculating the distance between the C and N atoms of
subsequent residues in the PDB ﬁle. A new chain is
deﬁned if the distance between the C atom of a residue
and the N atom of the next residue in the PDB ﬁle is larger
than 1.7 A ˚ . This value, which is signiﬁcantly larger than
the standard distance between two covalently linked C
and N atoms in a peptide bond (i.e. 1.33 A ˚ ), was chosen
in view of some abnormally long CN distances between
covalently linked residues in certain PDB ﬁles. It is, how-
ever, small enough to identify residues that are not cova-
lently linked, since the corresponding distance should not
be smaller than 3.8 A ˚ in the CHARMM force ﬁeld.
Similarly, disulﬁde bridges are automatically added when
the distance between two S atoms is lower than a thresh-
old of 2.25 A ˚ (the standard distance between two S atoms
in a S-S bond is 2.03 A ˚ , while two non-covalently linked S
atoms should not be closer than 3.95 A ˚ ). The CD1 atom
of isoleucine is renamed CD in agreement with the
CHARMM nomenclature. Selenomethionine residues,
which are often replacing methionine residues to facilitate
elucidating protein structures, are automatically replaced
by methionine residues and the atom names changed ac-
cordingly. Heme residues are automatically added to the
PSF when present. In that case, patches to link possible
histidine or cysteine residues to the Fe atoms are used. The
standard protonation state of residues at physiological
pH is applied to all residues, leading to negatively charged
aspartate and glutamate residues, positively charged lysine
and arginine residues and neutral serine, threonine,
tyrosine and cysteine residues. However, the protonation
state of histidine residues is determined automatically by
checking the chemical environment of the Ne and Nd
atoms of the imidazole ring. Protons are added, or not,
to these two atoms to allow possible hydrogen bonds with
nearby polar functions of the protein or water molecules,
and to prevent unfavorable contacts between a possible
NeHo rN dH function and another protonated function
or metal ion. When no contact is possible, the histidine is
protonated on Nd by default. The residue numbers given
in the PDB ﬁle are kept during the setup, to facilitate the
analysis of the docking results. Hydrogen atoms and
missing side chains are added automatically using the
HBUILD and IC BUILD commands of CHARMM.
Molecules not belonging to the protein part of the target
are added to the PSF if the corresponding compounds
exist in the standard CHARMM22/27 force ﬁeld.
Otherwise, they are removed from the system. However,
experimented users can take them into account by pro-
viding their own PSF/CRD ﬁles as mentioned below.
Water molecules are removed. The whole system is mini-
mized by 100 steps of steepest descent algorithm to remove
possible clashes due to atom additions or uncertainties in
the PDB ﬁle. During minimization, heavy atoms are
restrained using a 5kcal mol
 1 A
 2 constraint to
prevent unphysical motions. The root mean square devi-
ation between the starting and minimized conformations
is generally <0.15 A ˚ .
Preparation of the ligand. If a ZINC AC or a Mol2 ﬁle are
provided for the ligand, CHARMM topology, parameters
and coordinates, ﬁles are derived automatically (19) from
the Merck Molecular Force Field (MMFF) (28–32). In
brief, dihedral angle terms are taken as is, while only the
harmonic part of the bond, angle and improper terms are
retained. Charges are taken from MMFF. Van der Waals
Table 1. Inﬂuence of the ﬂexibility of the ligand on the success rate
observed with EADock DSS, the docking engine of SwissDock, in a
redocking assay carried out on 251 protein–ligand complexes
Max no. of
rotatable bonds
of the ligand
FDA-approved
drugs (%)
SR0 (%) SR5 (%)
56 3 8 4 9 3
10 93 77 86
15 99 69 83
20 100 66 81
As can be expected, the success rate decreases as the ligand ﬂexibility
increases. Interestingly, 93% of FDA-approved drugs have 10 or less
rotatable bonds. For 86% of such ligands in our data set, EADock is
able to propose a binding mode within 2 A ˚ root mean square deviation
to the experimental BM within among the ﬁve most favorable predic-
tions. See text for details.
Table 2. Inﬂuence of the fraction of the ligand which is buried upon
complexation (%BS) on the same data set
Min %BS SR0 (%) SR5 (%)
95 82 95
90 70 85
85 66 80
80 62 75
The more buried the ligands are, the more successful their dockings are.
See text for details.
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CHARMM22 (26). For consistency with CHARMM,
atoms with identical names are renamed.
Uploaded Mol2 ﬁles must contain all hydrogens and 3D
coordinates. The topology of the Mol2 ﬁles has to be
correct, hence we recommend the use of the following
software, working most of the time: UCSF Chimera,
OpenBabel (33), MarvinSketch (http://www.chemaxon
.com/) (save as MDL, then convert into Mol2 with
OpenBabel) and ChemDraw (34).
CONCLUSION
The SwissDock web server aims at providing a wide sci-
entiﬁc community with a free and user-friendly, yet state-
of-the-art protein/small molecule, docking tool. The auto-
matic setup of protein and ligand structures, the different
parameter presets and the convenient visualization and
analysis of docking predictions makes it accessible to a
wide audience. The EADock DSS engine behind
SwissDock is especially suited for drug design, with very
good success rates for small and relatively rigid ligands
with less than 10 ﬂexible rotatable bonds: the most favor-
able predicted BM is found within 2 A ˚ to the crystal struc-
tures for 77% of the 251 test complexes, and for 86% of
them, such a correct BM is found within the ﬁve most
favorable ones. This performance is even increased if the
ligand can be buried in a well-deﬁned binding site of its
target protein. The SwissDock web server is available at
http://www.swissdock.ch. We believe it constitutes a step
toward generalizing the use of docking tools beyond the
traditional molecular modeling community.
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